Publications

Filters: Keyword is Biomarkers, Tumor  [Clear All Filters]
Journal Article
Pang, Herbert, Keita Ebisu, Emi Watanabe, Laura Y. Sue, and Tiejun Tong. "Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis." Hum Genomics 5, no. 1 (2010): 5-16.
Li, Jialiang, and Jason P. Fine. "Assessing the dependence of sensitivity and specificity on prevalence in meta-analysis." Biostatistics 12, no. 4 (2011): 710-22.
Little, Paul, Dan-Yu Lin, and Wei Sun. "Associating somatic mutations to clinical outcomes: a pan-cancer study of survival time." Genome Med 11, no. 1 (2019): 37.
Diao, Guoqing, Jun Dong, Donglin Zeng, Chunlei Ke, Alan Rong, and Joseph G. Ibrahim. "Biomarker threshold adaptive designs for survival endpoints." J Biopharm Stat 28, no. 6 (2018): 1038-1054.
McLeod, Howard L.. "Cancer pharmacogenomics: early promise, but concerted effort needed." Science 339, no. 6127 (2013): 1563-6.
Hamy, Anne-Sophie, Sandrine Tury, Xiaofei Wang, Junheng Gao, Jean-Yves Pierga, Sylvie Giacchetti, Etienne Brain, Barbara Pistilli, Michel Marty, Marc Espié et al. "Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial." J Clin Oncol 37, no. 8 (2019): 624-635.
Laber, Eric B., Anastasios A. Tsiatis, Marie Davidian, and Shannon T. Holloway. "Discussion of "Combining biomarkers to optimize patient treatment recommendation"." Biometrics 70, no. 3 (2014): 707-10.
Zhao, Ying-Qi, and Michael R. Kosorok. "Discussion of combining biomarkers to optimize patient treatment recommendations." Biometrics 70, no. 3 (2014): 713-6.
Wang, Xiaofei, Jingzhu Zhou, Ting Wang, and Stephen L. George. "On Enrichment Strategies for Biomarker Stratified Clinical Trials." J Biopharm Stat 28, no. 2 (2018): 292-308.
Michiels, Stefan, Richard F. Potthoff, and Stephen L. George. "Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint." Stat Med 30, no. 13 (2011): 1502-18.
Jung, Sin-Ho. "Phase II cancer clinical trials for biomarker-guided treatments." J Biopharm Stat 28, no. 2 (2018): 256-263.
Secord, Angeles Alvarez, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, Chris J Brady, Heather A. Lankes, Herbert I. Hurwitz et al. "Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218." Clin Cancer Res 26, no. 6 (2020): 1288-1296.
Rashid, Naim U., Xianlu L. Peng, Chong Jin, Richard A. Moffitt, Keith E. Volmar, Brian A. Belt, Roheena Z. Panni, Timothy M. Nywening, Silvia G. Herrera, Kristin J. Moore et al. "Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer." Clin Cancer Res 26, no. 1 (2020): 82-92.
Pang, Herbert, and Xiaofei Wang. "Statistical aspect of translational and correlative studies in clinical trials." Chin Clin Oncol 5, no. 1 (2016): 11.
Nasution, Marlina D., and Xiaofei Wang. "Statistical issues and advances in cancer precision medicine research." J Biopharm Stat 28, no. 2 (2018): 215-216.
Barry, William T., Charles M. Perou, Kelly P Marcom, Lisa A. Carey, and Joseph G. Ibrahim. "The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies." J Biopharm Stat 25, no. 1 (2015): 66-88.